Impact of KIT mutation on efficacy of venetoclax and hypomethylating agents in newly diagnosed acute myeloid leukemia

Abstract Background The combination of venetoclax (VEN) with hypomethylating agents (HMAs) has emerged as a new standard treatment for older or unfit patients with acute myeloid leukemia (AML). However, the predictive factors for VEN/HMA efficacy remain unclear. In our study, we performed the first...

Full description

Bibliographic Details

Published in:	European Journal of Medical Research
Main Authors:	Wenxiu Shu, Qianqian Yang, Donghua He, Yi Li, Jing Le, Qianqian Cai, Hui Dai, Liufei Luo, Bingrong Chen, Yuan Gong, Dian Jin
Format:	Article
Language:	English
Published:	BMC 2025-05-01
Subjects:	Acute myeloid leukemia KIT Venetoclax Hypomethylating agents Chemotherapy Prognosis
Online Access:	https://doi.org/10.1186/s40001-025-02637-w